Amarantus BioScience Holdings, Inc.
AMBS · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.00 | -0.01 | 0.01 |
| FCF Yield | 1.41% | -136.55% | 19.46% | -41.26% |
| EV / EBITDA | -328.19 | -14.90 | 58.29 | -37.46 |
| Quality | ||||
| ROIC | 1.08% | 1.29% | 1.30% | 1.93% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | -0.15 | 0.96 | 1.18 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.38% | -83.20% | -84.69% | -91.79% |
| Free Cash Flow Growth | 100.59% | -438.51% | 172.71% | 81.81% |
| Safety | ||||
| Net Debt / EBITDA | -318.74 | -14.17 | 52.67 | -35.03 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |